Abstract: The invention discloses an application of phlegmyheatclear in preparation of a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease. The present invention studies the effect of phlegmyheatclear on model of rats with acute exacerbation of chronic obstructive pulmonary disease. Results show that high dose, middle dose, or low dose of phlegmyheatclear can, during the acute exacerbation of chronic obstructive pulmonary disease, improve the lung function of the rats and the pathological damage of lung tissues of the rats in different degrees, and it is dose dependent. High dose, middle dose, or low dose of phlegmyheatclear can improve inflammatory reaction in different degrees. For the drug effects, the high dose and the middle dose of phlegmyheatclear are better than the low dose of phlegmyheatclear. Therefore, phlegmyheatclear can be used to prepare a drug for treatment of acute exacerbation of chronic obstructive pulmonary disease.

Abstract: A use of bio-transformed bear bile powder in preparation of anti-inflammatory drugs is disclosed. The present invention carries out a comparative research on the anti-inflammatory drug activity of bio-transformed bear bile powder and natural bear bile powder. A research is made on the effect of the bio-transformed bear bile powder and natural bear bile powder on carrageenan-induced rat inflammation models, and a research is made on the effect of the bio-transformed bear bile powder on LPS-induced lung inflammation in mice. Experimental results show that the bio-transformed bear bile powder administration group obviously reduces plantar swelling of carrageenan-induced inflammation model in rats, and the effect thereof is not lower than that of the natural bear bile powder. Both the bio-transformed bear bile powder and the natural bear bile powder can significantly reduce levels of the inflammatory factors IL-6 and TNF-? in the lung and the serum.